Efinaconazole, sold under the brand name Jublia among others, is a triazole antifungal medication.

It is approved for use in the United States, Canada, and Japan as a 10% topical solution for the treatment of onychomycosis (fungal infection of the nail).

[6][7][8][9] Efinaconazole is an azole antifungal indicated in the US for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum and Trichophyton mentagrophytes.

[10][11] According to Valeant Pharmaceuticals International Inc CEO J. Michael Pearson they acquired Jublia through their purchase of Dow Pharmaceutical Sciences in 2008.

[12] In 2015, the cost of treatment with efinaconazole in the United States was said to be US$2,307 per nail.